Clinical Trials
2 trialsNCT05567185 2026-06-05
TAR-210
Janssen Pharmaceutical K.K.
Phase 1 Active not recruiting
NCT04572295 2026-03-11
A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer
Eisai Inc.
Phase 1 Active not recruiting